Life Sciences Update - February 2019

Life Sciences Update - February 2019

Welcome to the monthly update from the Life Sciences team at S&B containing news about recent and topical developments.

A link to the web version of this email update is available here. If you would like to receive these updates via email, please subscribe.

Contact our experts for further advice

View profile for Charlotte TillettCharlotte Tillett, View profile for Gustaf DuhsGustaf Duhs

Contents

  1. Court says no to Brexit get-out leaving tenant frustrated
  2. Court of Justice confirms that skinny label limits the marketing authorisation
  3. Employee post-termination confidentiality restrictions - less is more
  4. Preparing your workforce for Brexit
  5. S&B's Brexit Summit - Emergent Themes

  1. Court says no to Brexit get-out leaving tenant frustrated

    Canary Wharf Group v The European Medicines Agency (EMA) has been the most eagerly anticipated case of the year so far with commentators predicting serious ramifications for the property industry if the EMA succeeded. The industry will however now be breathing a huge sigh of relief as the High Court gave short shrift to the EMA’s request that the court effectively tear up its lease in light of Brexit. 

    Read more

  2. Court of Justice confirms that skinny label limits the marketing authorisation

    The Court of Justice of the European Union (CJEU) has confirmed that where a generic company has omitted - ‘carved out’ - patented indications or dosage forms from the Summary of Product Characteristics (SmPC) and product labelling in order to... Read more

  3. Employee post-termination confidentiality restrictions - less is more

    Trade secrets are often key assets for science and technology businesses, and the people who know and understand these assets best are its highly-skilled employees. Leakage when these employees move on is, therefore, the kind of thing that keeps people awake... Read more

  4. Preparing your workforce for Brexit

    Changes to the immigration system post-Brexit look likely to come at a time when the life sciences sector is already facing significant challenges. Pharmacists warn of the increasing number of drugs on the supply shortage list, and so any disruption to supply chains as a result of Brexit is likely to cause even more severe shortages in the UK. Published in PharmaTimes. Read more

  5. S&B's Brexit Summit - Emergent Themes

    On Tuesday 22 January 2019 - some 66 days before Brexit - we hosted a Brexit Summit, which considered the process and some of the key legal issues affecting businesses on a no deal Brexit, with presentations covering Immigration; Commercial Trading Risk; International Arbitration; Intellectual Property; Competition; Regulatory; Employment and Data Privacy law.

    The event was well attended by many of the firm’s key clients and contacts.  Delegates were from a variety of businesses, from global corporates to owner managed businesses, and across many of the UK’s key sectors, from financial services to FMCG. 

    The following note sets out some of the key themes that emerged from the roundtable and Q&A sessions.  It is by no means comprehensive or scientific, but is intended to give a snapshot of issues raised by businesses at this current phase of withdrawal.

Search our site